Table 1. Baseline characteristics of patients and univariate regression analysis for admission platelet count.
| Variables | Characteristics | Univariate analysis |
|---|---|---|
| β (95% CI) p value | ||
| Number (n) | 130 | |
| Age (year) | 46.86 ± 10.52 | −1.166 (−2.287, −0.045) 0.0436 |
| Sex | ||
| Females, n (%) | 32 (24.615) | 1 |
| Males, n (%) | 98 (75.38) | −30.126 (−57.347, −2.905) 0.0319 |
| BMI (kg/m2) | 25.90 ± 3.44 | 0.567 (−2.883, 4.017) 0.7478 |
| History of smoking, n (%) | 66 (50.77) | −20.098 (−43.725, 3.528) 0.0979 |
| History of hypertension, n (%) | 94 (72.31) | −0.518 (−27.200, 26.163) 0.9697 |
| History of DM, n (%) | 4 (3.08) | 47.452 (−21.194, 116.099) 0.1778 |
| Attack time (d) | 2.00 (1.00–5.00) | 11.229 (8.266, 14.193) <0.0001 |
| Preoperative SBP (mm Hg) | 113.24 ± 18.24 | 0.106 (−0.555, 0.766) 0.7537 |
| Preoperative DBP (mm Hg) | 56.02 ± 11.89 | 0.059 (−0.954, 1.073) 0.9090 |
| LVEF (%) | 62.58 ± 8.39 | −0.636 (−2.070, 0.798) 0.3863 |
| LVEDD (mm) | 51.40 ± 7.47 | 0.953 (−0.685, 2.591) 0.2564 |
| EuroSCORE# | 5 (5, 6) | −3.831 (−14.966, 7.304) 0.5013 |
| 3 n (%) | 19 (14.62) | - |
| 4 n (%) | 5 (3.85) | - |
| 5 n (%) | 69 (53.08) | - |
| 6 n (%) | 30 (23.08) | - |
| 7 n (%) | 5 (3.85) | - |
| 8 n (%) | 2 (1.54) | - |
| Aortic regurgitation (n=129) | ||
| Non-regurgitation n (%)* | 27 (20.93) | 1 |
| Mild-regurgitation n (%) | 52 (40.31) | 18.137 (−14.242, 50.517) 0.2744 |
| Moderate-regurgitation n (%) | 22 (17.05) | 4.008 (−35.197, 43.213) 0.8415 |
| Severe-regurgitation n (%) | 28 (21.71) | 5.930 (−30.888, 42.748) 0.7528 |
| Serum variables | ||
| Hb (g/L) | 12.80 (11.90–13.50) | 0.342 (−0.748, 1.432) 0.5399 |
| WBC (109/L) | 9.44 (7.54–10.82) | −3.319 (−6.834, 0.197) 0.0666 |
| LAC (mmol/L) | 1.00 (0.80–1.40) | −8.312 (−20.265, 3.642) 0.1753 |
| Coagulation/fibrinolysis | ||
| FIB (g/L) | 3.78 (2.85–4.62) | 4.718 (−3.982, 13.418) 0.2899 |
| FDP (mg/L) | 10.20 (6.20–18.70) | −0.831 (−1.305, −0.358) 0.0008 |
| PAI-1 (ng/mL) | 0.71 ± 0.19 | −5.119 (−67.795, 57.557) 0.8731 |
| TF (ng/mL) | 3.48 (2.62–4.88) | 0.293 (−4.546, 5.133) 0.9056 |
| TFPI (ng/mL) | 146.42 ± 65.20 | 0.257 (0.079, 0.436) 0.0054 |
| Inflammatory | ||
| IL-6 (pg/mL) | 56.19 (46.47–70.50) | 0.170 (−0.353, 0.693) 0.5247 |
| IL-10 (pg/mL) | 78.38 (43.68–114.85) | 0.176 (−0.029, 0.380) 0.0946 |
| HLE (ng/mL) | 2.23 (1.67–2.63) | 3.457 (−6.048, 12.961) 0.4772 |
| TNFα (pg/mL) | 53.77 (38.61–70.78) | 0.091 (−0.295, 0.478) 0.6444 |
| ROS | ||
| MDA (nmol/mL) | 3.30 ± 0.59 | −12.927 (−33.006, 7.151) 0.2093 |
| MPO (units/L) | 46.93 ± 15.01 | 0.541 (−0.269, 1.350) 0.1932 |
| TAOC (units/mL) | 7.17 ± 1.87 | .713 (−2.659, 10.085) 0.2555 |
| TSOD (units/mL) | 109.15 ± 42.86 | 0.058 (−0.231, 0.347) 0.6964 |
| Platelet and endothelial cell | ||
| Platelet count (109/L) | 168.77 (136.25–204.00) | - |
| VEGF (pg/mL) | 198.92 (135.86–338.26) | −0.012 (−0.068, 0.044) 0.6757 |
| PGI2 (pg/mL) | 49.69 (25.19–103.20) | 0.026 (−0.098, 0.150) 0.6807 |
| TXB2 (pg/mL) | 154.82 ± 98.94 | −0.120 (−0.240, −0.001) 0.0502 |
Data are given as numbers, percentage, mean ± standard deviation or median IQR. *: Non-regurgitation group is the reference group. #: EuroSCORE is defined as continuous variable. BMI: Body Mass Index; CI: confidence interval; DM: diabetes mellitus; DBP: upper limb diastolic blood pressure; EuroSCORE: European system for cardiac operative risk evaluation; FDP: fibrinogen degradation product; FIB: fibrinogen; Hb: hemoglobin; HLE: human leukocyte elastase; IL: interleukin; LAC: lactic acid; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter; MDA: methane dicarboxylic aldehyde; MPO: myeloperoxidase; PGI2: prostaglandin I2; PLC: platelet count; ROS: reactive oxygen species; SBP: upper limb systolic blood pressure; TAOC: total anti-oxidation capacity; TSOD: total superoxide dismutase; TF: tissue factor; TFPI: tissue factor pathway inhibitor; TNFα: tumor necrosis factor α; TXB2: thromboxane B2; VEGF: vascular endothelial growth factor; WBC: white blood cells; IQR: interquartile range; PAI-1: plasminogen activator inhibitor-1